Analisis of Facors Involved in Antidepressant Treatment Response of Major Depressive Disorder

Major Depressive Disorder Clinical Trial

— AFADTRMDD  

Official title:

Treatment Response Study of Sertraline to Treat Japanese Major Depressive Disorder

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01454635
• Other study ID #: SU-GEC-84
• Status: Completed
• Phase: N/A
• First received: October 17, 2011
• Last updated: October 27, 2011
• Start date: June 2008
• Est. completion date: March 2010

Study information

• Verified date: October 2011
• Source: Showa University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to predict and visualize sertraline treatment response in major depressive disorder with clinical symptoms, demographic and stress state, personality, eight genetic polymorphisms at baseline.

Description:

While only about 50% of patients respond to first treatment in major depressive disorder, 30-40% did not remit after continuous 1 year treatment. However, patients must remain on their prescribed medications for at least 4 weeks without knowing whether the particular antidepressant will be effective. Studies have suggested a number of predictors of treatment response, but varying degrees of success and nearly all with poor prognostic sensitivity and specificity. The investigators investigated clinical symptoms, demographic and stress state, personality and genetic polymorphisms in patients of major depressive disorder treated with sertraline and performed multivariate analysis to extract the predicting factors. Moreover, the investigators tried to visualize weight of variables and pathway one another.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 96
• Est. completion date: March 2010
• Est. primary completion date: March 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• clinical diagnosis of Major Depressive Disorder

• Must be able to swallow tablets

Exclusion Criteria:

• pregnant

• breastfeeding

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Disease
• Major Depressive Disorder

Intervention

Drug:
• Sertraline
dosage,frequency and duration

Locations

Country	Name	City	State
Japan	Showa University Northern Yokohama Hospital	Yokohama	Kanagawa

Sponsors (1)

Lead Sponsor	Collaborator
Showa University

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Hamilton Rating Scale for Depression		8 weeks